TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03737474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
Study: NCT03080428

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Genomic test
Description: genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
Study: NCT02869152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic injection of ICG
Description: Dye injection around the rectal tumor for SLN mapping with NIR imaging.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic injection of Spot
Description: Dye injection for tattooing rectal tumor prior to surgical resection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Description: Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dyes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic NIR imaging and gamma probe
Description: Endoscopic near infrared (NIR) imaging of ICG and detection of radiotracer with gamma probe after standard removal of rectal neoplasm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dissection of sentinel lymph node(s)
Description: Surgical removal of identified lymph nodes in the rectum.
Study: NCT00648609

Intervention type: OTHER
Intervention: Palliative home care in advanced COPD
Description: Interdisciplinary palliative care team on community based self care management of advanced COPD.

Intervention type: OTHER
Intervention: Standard of care
Description: Usual care for COPD patients
Study: NCT01798043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with pacemaker stimulation
Description: Patient is undergoing a Cardiac MRI at enrollment and 12 months later

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with pacemaker stimulation
Description: Patient is undergoing a Cardiac MRI at enrollment and 12 months later

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with and without pacemaker stimulation
Description: Patient is undergoing a Cardiac MRI at enrollment and 12 months later

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with and without pacemaker stimulation
Description: Patient is undergoing a Cardiac MRI at enrollment and 12 months later
Study: NCT03682419

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VKA Patients
Description: Venepuncture and capillary blood collection from Patients receiving Warfarin Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VKA Patients
Description: Venepuncture and capillary blood collection from Patients receiving Warfarin Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-VKA Patients
Description: Venepuncture and capillary blood collection from Patients not receiving Warfarin Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-VKA Patients
Description: Venepuncture and capillary blood collection from Patients not receiving Warfarin Therapy
Study: NCT04395976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ayurveda
Description: The Ayurveda intervention is multimodal and following the principles of Ayurveda as a whole medical system, each participants will be treated with individualised care. From the range of proven Ayurvedic Herbs, combination will be decided based on individual participants, his symptoms and his personality.
Study: NCT01167075

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresubin Original

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intestamin plus Fresubin Original
Study: NCT01314313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR Implantation with SAPIEN XT
Description: Operable Group with SAPIEN XT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SAVR Implantation
Description: Control Group
Study: NCT00830882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levosalbutamol
Description: 2 puffs four times a day for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: racemic salbutamol
Description: 2 puffs four times a day for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 puffs four times a day for 2 weeks
Study: NCT00796939

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Green light mask
Description: Participants will receive approximately 10,000 lux from green light-emitting diodes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Red Light Mask
Description: Participants will receive approximately 0.5 lux from white light-emitting diodes covered by a red gel.
Study: NCT01213888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trientine Hydrochloride
Description: All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10-day course of oral Trientine at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo capsules
Description: All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions
Study: NCT00836693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: 5 milligrams (mg) administered orally once a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet administered orally once a day for 12 weeks.
Study: NCT04195763

Intervention type: DRUG
Intervention: asfotase alfa
Description: This is an observational study and no intervention will be administered. All participants will be treated by their physician in accordance with standard of care. All medications are commercially available and will be used as directed by the treating physician.
Study: NCT03098875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: General anesthesia using sevoflurane as a hypnotic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General anesthesia using propofol as a hypnotic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: General anesthesia using remifentanil as an analgesic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: General anesthesia using remifentanil as an analgesic.
Study: NCT00578539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA C
Description: Ara C (3000 mg/m2) IV every 12 hours for 6 doses (days -8 to -5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (45mg/kg) IV once daily on day -7 and day -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MESNA
Description: MESNA (45mg/kg; divided into 5 doses) will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI: total dose 14.0 Gy, will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Campath-1h
Description: CAMPATH (3 mg IV for patients between 5 and 15 kg; 5 mg for patients between 16 and 30 kg; and 10 mg for patients greater than 30 kg) will be given on day -4, day -3, day -2 and day-1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem cells are infused on day 0
Study: NCT01125592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IonCLeanse Footbath
Description: Application of an ionic footbath for 30 minutes per week for 4 weeks
Study: NCT04718077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraosseus
Description: IO dexamethasone injection Dexamethasone 4 mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Submucoal
Description: SM dexamethasone injection Dexamethasone 4 mg
Study: NCT02231086

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjuvant HIPEC (open/laparoscopic)
Description: Adjuvant HIPEC procedure: access to the abdominal cavity by laparoscopy or laparotomy under general anaesthesia, adhesiolysis if necessary, complete staging of the intra-abdominal cavity, positioning of in- and outflow catheters, perfusion with a minimum of 2l isotonic dialysis fluid at a flow rate of 1-2l/min and an inflow temperature of 42-43˚C. Before the beginning of HIPEC, 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (460 mg/m2) is added to the perfusate after attaining at least 42 degrees inflow temperature with a total of 30 minutes perfusion time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard adjuvant systemic chemotherapy
Description: Colon cancer patients with a high risk of developing PC, but do not have (yet) proven macroscopic peritoneal metastasis, are standardly treated with adjuvant systemic chemotherapy. Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard adjuvant systemic chemotherapy
Description: Colon cancer patients with a high risk of developing PC, but do not have (yet) proven macroscopic peritoneal metastasis, are standardly treated with adjuvant systemic chemotherapy. Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Description: Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively in both study arms.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic laparoscopy
Description: Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively in both study arms.
Study: NCT03780244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra Aesthetic 8ml
Description: Treatment of nasolabial folds

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sculptra Aesthetic 5ml
Description: Treatment of nasolabial folds
Study: NCT01222052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel
Description: Arm A 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks~Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel
Description: Arm A 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks~Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks
Study: NCT02389296

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires will be distributed to nursing staff

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires will be distributed to nursing staff
Study: NCT02946723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Lead implantation surgery for SNM using ultrasound guided technique

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: X-ray
Description: Lead implantation surgery for SNM using X-ray technique
Study: NCT01695226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: pre-operative celecoxib (400 mg) twice daily for two to three weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pre-operative placebo twice daily for two to three weeks
Study: NCT03080428

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Genomic test
Description: genomic test realized on surgery block or formalin-fixed paraffin-embedded slides

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Genomic test
Description: genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
Study: NCT04424134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine and Spironolactone
Description: Bromhexine 8 mg x 4 times a day x 10 days Spironolactone 50 mg x once a day x 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Base therapy
Description: Therapy currently recommended by Ministry of Health of Russian Federation for COVID 19 treatment
Study: NCT01323114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic duodenal exclusion
Description: Laparoscopically-performed Roux-en Y intestinal bypass of the duodenum and proximal jejunum; stomach remains normal size and proximal division performed just distal to pylorus.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Treatment
Description: Standard of care medical treatment for type 2 diabetes to include medications and dietary management under the monitoring of the study endocrinologist.
Study: NCT00169897

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation (teaching and exercise)
Description: After a 4-week education program, patients took part to home-based rehabilitation or outpatient hospital-based rehabilitation for 8 weeks. Patients were subsequently followed for 40 weeks to complete the one-year study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (teaching and exercise)
Description: After a 4-week education program, patients took part to home-based rehabilitation or outpatient hospital-based rehabilitation for 8 weeks. Patients were subsequently followed for 40 weeks to complete the one-year study.
Study: NCT01248546

Intervention type: PROCEDURE
Intervention: Digital breast tomosynthesis
Description: The participants included in the trial will have an additional radiation exposure for breast tomosynthesis
Study: NCT01372098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NFP + IPV intervention
Description: The intervention focuses on helping women stay safe in a relationship. Strategies for overcoming barriers to using and accessing community resources and services, and community agency interventions for women exposed to IPV is built into the intervention.
Study: NCT04017676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervision assissted by measures
Description: In the weeks 10 and 13, about 72 hours after the meeting scheduled for that week, and before the next therapeutic session, there will be a structured training session (based on the recommendations of Krägeloh et al., 2015), based on information in the literature about the various questionnaires
Study: NCT00352911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VGX-410 (Mifepristone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VGX-410 (Mifepristone)
Study: NCT01295177

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topic cream insulin
Description: Intervention: Placebo cream versus insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream or insulin cream. The placebo or insulin were used for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topic cream insulin
Description: Intervention: Placebo cream versus insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream or insulin cream. The placebo or insulin were used for 8 weeks.
Study: NCT01173406

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPAP education
Description: Standard CPAP education plus an session and one telephone follow up

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: CPAP education
Description: Standard CPAP education plus an session and one telephone follow up
Study: NCT03876860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone Dilator
Description: Addition of silicone band to standard vaginal dilator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dilator
Description: Standard vaginal dilator
Study: NCT04375020

Intervention type: DRUG
Intervention: GABA
Description: GABA nutritional supplement 750mg per day for 6 months
Study: NCT03995667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy
Description: Optune-Tumor Treating Fields (TTFields). Transducer arrays affixed to scalp, worn continuously.
Study: NCT03364712

Intervention type: OTHER
Intervention: routine medical care, venipuncture

Intervention type: OTHER
Intervention: routine medical care, venipuncture
Study: NCT04538456

Intervention type: OTHER
Intervention: questionnaire and optional interview
Description: Participants will be sent an online or paper questionnaire. If participants have expressed an interest in taking part in an interview, they may be contacted by a member of the research team. The interviews will be conducted over the phone at time suitable for the participant. There will be no study specific hospital visits.

Intervention type: OTHER
Intervention: questionnaire and optional interview
Description: Participants will be sent an online or paper questionnaire. If participants have expressed an interest in taking part in an interview, they may be contacted by a member of the research team. The interviews will be conducted over the phone at time suitable for the participant. There will be no study specific hospital visits.
Study: NCT03736473

Intervention type: DRUG
Group type: OTHER
Intervention: MEDI9447 (oleclumab)
Description: MEDI9447 administered intravenously
Study: NCT02949804

Intervention type: BEHAVIORAL
Intervention: Comparison between two groups
Description: Comparison will be made between smokers and non smokers regarding vasovagal tendency

Intervention type: BEHAVIORAL
Intervention: Comparison between two groups
Description: Comparison will be made between smokers and non smokers regarding vasovagal tendency
Study: NCT02950064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTP-114
Description: Part 1 (Escalation) IV treatment of BTP-114 in 21-day cycles. Doses will be increased in sequential cohorts until the maximum tolerated dose is determined which will lead to the recommended phase 2 dose~Part 2 (Expansion) 5 cohorts of patients will be treated at the RP2D of IV BTP-114 in 21-day cycles for the tumor types pancreatic cancer, castration-resistant prostate cancer, ovarian cancer, triple-negative breast cancer and deoxyribonucleic acid (DNA) repair mutation-positive advanced solid tumors.
Study: NCT03723876

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body awareness therapy
Description: The physiotherapist uses body awareness techniques, i.e. guiding the participant in movement qualities such as stability, breathing, flow and grounding. Conscious awareness focused on bodily experiences is a key component to be able to reflect on what your body signals.~As a baseline a standardized observation of the movement quality of the individual is performed. The physiotherapist needs special education in the body awareness technique used, to rightly perform and analyse the observation and administer the intervention.~The aim of the body awareness therapy is to raise physical and mental awareness by strengthening the interplay between sensory impressions and motor ability and to gain knowledge of own movement patterns that are not functional and to form alternatives to these.
Study: NCT05764941

Intervention type: DRUG
Intervention: Inetetamab
Description: 8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.

Intervention type: DRUG
Intervention: Pyrotinib
Description: 400mg, oral, every day.

Intervention type: DRUG
Intervention: Vinorelbine
Description: 25 mg/m2, D1, D8, every 3 weeks for one cycle.
Study: NCT02910739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-8931
Description: MK-8931 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8931
Description: MK-8931 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-8931
Description: MK-8931 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8931
Description: MK-8931 40 mg
Study: NCT02391779

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BeneFlax®
Description: Daily ingestion of 600 mg SDG/day in 1.6 g SDG-enhanced flax lignan (BeneFlax®) with walking training or flexibility training

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BeneFlax®
Description: Daily ingestion of 600 mg SDG/day in 1.6 g SDG-enhanced flax lignan (BeneFlax®) with walking training or flexibility training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking training
Description: 30-60 minutes walking training, 5 days/week.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Walking training
Description: 30-60 minutes walking training, 5 days/week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Walking training
Description: 30-60 minutes walking training, 5 days/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexibility training
Description: 5 days/week; e.g. stretching training at home

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Flexibility training
Description: 5 days/week; e.g. stretching training at home

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Whey Protein)
Description: 0.6 g/day (an amount equal in volume to BeneFlax®) with walking training or flexibility training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dash Eating Plan
Description: Dietary Approaches to Stop Hypertension (DASH), a balanced eating plan - all participants in all treatment arms will be encouraged to adopt a DASH eating plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dash Eating Plan
Description: Dietary Approaches to Stop Hypertension (DASH), a balanced eating plan - all participants in all treatment arms will be encouraged to adopt a DASH eating plan.